Abstract
Background Infections with human papillomaviruses (HPV) may enter into a latent state in epithelial basal cells, and eventually become reactivated following loss of immune control. It is unclear what proportion of incident detections of HPV are due to reactivation of previous latent infections versus new transmissions.
Methods The HITCH cohort study prospectively followed young newly-formed heterosexual partners recruited between 2005-2011 in Montréal, Canada. We calculated the fraction of incident HPV detections non-attributable to sexual transmission risk factors with a Bayesian Markov state transition model. Results are the median (2·5-95·5th percentiles) of the estimated posterior distribution.
Findings 544 type-specific incident HPV detection events occurred in 849 participants; 32·5% of all incident HPV detections occurred in participants whose HITCH partners were negative for that HPV type and who did not report having sex with anyone else over follow-up. We estimate that 42·7% (38·4-47·2%) of all incident HPV detections in this population might be attributable to reactivation of latent infections, not transmission.
Interpretation A positive HPV test result in many cases may be a reactivated past infection, rather than a new infection from recent sexual behaviors or partner infidelity. The potential for reactivation of latent infections in previously HPV-negative women should be considered in the context of cervical cancer screening.
Funding Canadian Institutes of Health Research, National Institutes of Health, Merck-Frosst Canada Ltd, Merck & Co Ltd, Fonds de la Recherche en Santé du Québec.
Evidence before this study Previous studies assessing the proportion of HPV infections attributable to reactivation in women have been conducted in individual-based studies. Determining this estimate using a couple-based study design could account for the partner’s HPV status and rule out sexual transmission. Authors from this current study recently published a systematic review that aimed to identify all published couple-based studies measuring HPV transmission. They searched MEDLINE, EMBASE, Scopus, and Cochrane Library from database inception to December 1, 2019, with no language restrictions using the keywords and MeSH terms “HPV,” “papillomavirus infections,” “papillomaviridae,” “transmission,” “heterosexuality,” “couples,” and “sexual partners”. Studies were included if the study population was heterosexual couples, genital samples were collected from each partner, and HPV transmission rates were reported. The search yielded 834 records, of which seven couple-based studies were eligible to be included in the systematic review. None of the identified studies measured the proportion of HPV infections attributable to reactivation.
Added value of this study This study presents the first analysis assessing reactivation of HPV infections using a couple-based study design. We recruited young heterosexual couples and collected genital HPV data from both partners, allowing us to control for the sexual partner’s HPV status. We estimate that 57% of the newly detected incident HPV infections in women could be attributed to sexual transmission while the remaining 43% is most likely due to reactivation of latent infections.
Implications of all the available evidence In the context of cervical cancer screening, our findings suggest that women who have previously tested HPV negative may not remain HPV-negative, even with no new sexual partners, due to reactivation of a latent infection. This underscores the importance for HPV-negative women to undergo multiple screenings in their lifetime. In addition, the sizeable proportion of newly detected HPV infections attributable to reactivation suggests that a positive HPV test is not necessarily due to recent sex or partner infidelity, which may help de-stigmatize a positive HPV test result.
Competing Interest Statement
TM, AM, ANB, and PPT have no conflicts of interest to disclose. FC reports grants paid to his institution from Becton Dickinson, Roche Molecular systems, and Merk Sharp and Dome outside of the submitted work, as well as from Canadian Institutes of Health Research (CIHR), CANFAR and the Fonds de la recherche en Santé du Québec. ELF reports grants to his institution from CIHR, the National Institutes of Health, and Merck during the conduct of the study; and personal fees from Merck. MZ and ELF hold a patent related to the discovery "DNA methylation markers for early detection of cervical cancer", registered at the Office of Innovation and Partnerships, McGill University, Montreal, Quebec, Canada.
Clinical Protocols
Funding Statement
This work was supported by the Canadian Institutes of Health Research [operating grant 68893, team grant 83320, and foundation grant 143347 to ELF]; the National Institutes of Health [grant AI073889 to ELF]; supplementary and unconditional funding by Merck-Frosst Canada Ltd and Merck & Co Ltd.; the Reseau FRSQ Fonds de la Recherche en Sante du Quebec AIDS and Infectious Disease Network [for optimization of molecular techniques to FC]; the Cancer Research Society [Fellowship Award to TM]; the McGill Faculty of Medicine [Internal Studentship, Gershman Memorial Fellowship, and Dr. John A. Lundie Research Fellowship to AM]; the Canada Research Chair in Sexually Transmitted Infection Prevention [to ANB]; and the University of Toronto Department of Family and Community Medicine [Non-Clinician Scientist Award to ANB]. The funders played no role in the writing of the manuscript, the collection/analysis of the data, or the decision to submit it for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethical review committees of McGill University, Concordia University, and the Centre Hospitalier de l'Université de Montréal approved the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Participation consent forms specified that the participant data would only be published in aggregate form, and that individual-level participant data would only be made available to investigators involved in the HITCH study. To access individual-level HITCH data, please contact eduardo.franco{at}mcgill.ca. The protocol for the HITCH cohort study has been published by El-Zein et al. 2019 (https://doi.org/10.2196/11284). Code used for the analysis can be found in the supplementary material.
